CASI Pharmaceuticals, Inc.
CASIDrugs in Pipeline
12
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 1, 2026
12wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
pemetrexed
Advanced Cancer
Sunitinib Malate
Metastatic Renal Cell Carcinoma
recombinant human Angiostatin protein
Carcinoma, Non-Small-Cell Lung
CID-103
Chronic Immune Thrombocytopenia
Panzem NCD
Recurrent Glioblastoma Multiforme
ENMD-2076
Ovarian Cancer
MKC-1
Ovarian Cancer
Panzem Nanocrystal Colloidal Dispersion (NCD)
Ovarian Cancer
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Carcinoid Tumor
2-methoxyestradiol
Relapsed Multiple Myeloma
Panzem Nanocrystal Colloidal Dispersion
Recurrent Glioblastoma Multiforme
Panzem® NCD
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pemetrexed | Phase 2 | Advanced Cancer | - | Patent 2036 |
Sunitinib Malate | Phase 2 | Metastatic Renal Cell Carcinoma | - | |
recombinant human Angiostatin protein | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
CID-103 | Phase 2 | Chronic Immune Thrombocytopenia | - | - |
Panzem NCD | Phase 2 | Recurrent Glioblastoma Multiforme | - | - |
ENMD-2076 | Phase 2 | Ovarian Cancer | - | - |
MKC-1 | Phase 2 | Ovarian Cancer | - | - |
Panzem Nanocrystal Colloidal Dispersion (NCD) | Phase 2 | Ovarian Cancer | - | - |
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | Phase 2 | Carcinoid Tumor | - | - |
2-methoxyestradiol | Phase 2 | Relapsed Multiple Myeloma | - | - |
Panzem Nanocrystal Colloidal Dispersion | Phase 2 | Recurrent Glioblastoma Multiforme | - | - |
Panzem® NCD | Phase 2 | Prostate Cancer | - | - |
Ovarian Cancer
3 drugs in this indication
Recurrent Glioblastoma Multiforme
2 drugs in this indication
Metastatic Renal Cell Carcinoma
1 drug in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Chronic Immune Thrombocytopenia
1 drug in this indication
Advanced Cancer
1 drug in this indication
Relapsed Multiple Myeloma
1 drug in this indication
Prostate Cancer
1 drug in this indication
Carcinoid Tumor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)